Core Viewpoint - Tonghe Pharmaceutical (SZ 300636, closing price: 8.77 yuan) announced on August 4 that it has received an invention patent certificate from the National Intellectual Property Administration for a method of preparing the intermediate of Remogliflozin [2] Company Summary - The patent is titled "A Preparation Method for an Intermediate of Remogliflozin" [2]

证券代码：300636 证券简称：同和药业 公告编号：2025-040 专利号：ZL 2023 1 0869300.2 专利类型：发明专利 专利申请日：2023.07.17 授权公告日：2025.08.01 专利权人：江西同和药业股份有限公司 江西同和药业股份有限公司 关于取得发明专利证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 江西同和药业股份有限公司（以下简称"公司"）于近日收到国 家知识产权局颁发的发明专利证书，具体情况如下： 发明名称：一种瑞美吉泮中间体的制备方法 注：专利权自授权公告之日起生效。专利权期限为二十年，自申请日起算。 本发明涉及一种瑞美吉泮关键中间体的制备方法，瑞美吉泮是一 种临床用于治疗偏头痛的药物。本发明提供的制备方法可以显著降低 瑞美吉泮关键中间体的制备成本，更适合于工业化生产。 上述发明专利的取得不会对公司近期生产经营产生重大影响，但 有利于发挥公司自主知识产权技术优势，完善知识产权保护体系，从 而增强公司核心竞争力。 特此公告。 江西同和药业股份有限公司董事会 二〇二五年八月四日 1/ 1 ...

Investment Rating - The report recommends a "Buy" rating for multiple companies in the pharmaceutical sector, including Junshi Biosciences, Hualan Biological Engineering-B, and others [3]. Core Insights - The pharmaceutical sector has shown a 1.90% increase this week, outperforming the CSI 300 index by 0.21 percentage points. Sub-sectors such as pharmaceutical outsourcing, vaccines, and medical consumables performed well, while innovative drugs lagged behind [6][42]. - The report emphasizes the potential of the 4-1BB target in cancer treatment, particularly the PD-L1/4-1BB bispecific antibodies, which may address the limitations of PD-1/PD-L1 monotherapy [5][16][17]. Summary by Sections Industry Viewpoints and Investment Recommendations - 4-1BB is recognized as a promising target for tumor therapy, enhancing T cell activation and survival, which is crucial for effective immune responses against cancer [16]. - Investment strategies focus on the innovative drug sector, driven by increased liquidity and risk appetite, with a recommendation to pay attention to companies with strong pipelines in bispecific antibodies and ADCs [6][38]. Pharmaceutical Industry Market Performance - The pharmaceutical sector's overall P/E ratio is reported at 30.67 times, with a premium of 40.37% compared to the overall A-share market excluding financials [42]. Company Dynamics - Notable company developments include: - LIZHU Group's successful Phase III trial for a monoclonal antibody for psoriasis [43]. - Baiyang Pharmaceutical's planned share reduction by its major shareholder [43]. - Mylab's new medical device approval, enhancing market competitiveness [44]. Industry Dynamics - The report highlights the increasing focus on innovative drug development and the potential for significant market opportunities in the context of upcoming patent expirations for key small molecule drugs [38].

Core Viewpoint - The company has received market access approval for its active pharmaceutical ingredients, Agomelatine and Oxycodone, in South Korea, which will positively impact its international market expansion efforts [1] Group 1 - The company announced the receipt of drug registration certificates from the South Korean Ministry of Food and Drug Safety [1] - The approval signifies that Agomelatine and Oxycodone have gained entry into the South Korean market [1] - This development is expected to enhance the company's ability to expand its international business operations [1]

Core Viewpoint - The company Tonghua Dongbao Pharmaceutical has received registration certificates from the Korean Ministry of Food and Drug Safety (MFDS) for two drugs, Agomelatine and Opicapone, which will enhance its international market presence [1] Group 1: Drug Approvals - Agomelatine is indicated for the treatment of adult depression [1] - Opicapone is a COMT inhibitor primarily used for the treatment of Parkinson's disease and Parkinson's syndrome [1] Group 2: Market Impact - The approval of Agomelatine and Opicapone for the Korean market will positively contribute to the company's efforts to expand its international business [1]

完整，没有虚假记载、误导性陈述或重大遗漏。 江西同和药业股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日召开第四届董事会第四次会议审议通过了《关于 2022 年限制性 股票激励计划首次授予部分第三个限售期解除限售条件未成就及回 购注销部分限制性股票的议案》，鉴于公司 2022 年限制性股票激励计 划部分激励对象离职及首次授予部分、暂缓授予部分第三个解除限售 期解除限售条件未成就，同意根据《江西同和药业股份有限公司 2022 年限制性股票激励计划》的相关规定回购注销前述所涉激励对象已获 授但未解除限售的合计 1,575,855 股限制性股票。回购注销完成后， 公司总股本由 42,152.7350 万股变更为 41,995.1495 万股，注册资本 由 42,152.7350 万 元 变 更 为 41,995.1495 万 元 ， 投 资 总 额 由 42,152.7350 万元变更为 41,995.1495 万元。 公司于 2025 年 5 月 16 日召开了 2024 年年度股东大会，审议通 过了《关于 2022 年限制性股票激励计划首次授予部分第三个限售期 解除限售条件未成就及回购注销部分 ...

证券代码：300636 证券简称：同和药业 公告编号：2025-038 江西同和药业股份有限公司 关于公司获得韩国药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 江西同和药业股份有限公司（以下简称"公司"）于近日收到韩 国食品药品安全部（MFDS）颁发的阿戈美拉汀、奥吡卡朋药品注册证 书，相关信息如下： 1、阿戈美拉汀药品注册证书 生产商名称：江西同和药业股份有限公司 生产商地址：江西省奉新高新技术产业园区 2、奥吡卡朋药品注册证书 生产商名称：江西同和药业股份有限公司 生产商地址：江西省奉新高新技术产业园区 认证范围：奥吡卡朋原料药 证书编号：2025-A1-1644 签发日期：2025.07.17 阿戈美拉汀适用于治疗成人抑郁症。 认证范围：阿戈美拉汀原料药 证书编号： 2025-A1-1548 签发日期：2025.07.02 公司进一步扩大国际市场业务起到积极作用。由于医药行业的特点， 相关产品在国际市场的销售情况易受到市场环境变化、汇率波动等因 素影响，敬请广大投资者谨慎决策，注意防范投资风险。 特此公告。 江西同和药业股份有限公司 ...

Market Overview - The Shanghai Composite Index closed at 3519.65 points, above the annual line, with a change of 0.27% [1] - The total trading volume of A-shares reached 14809.22 billion yuan [1] Stocks Breaking Annual Line - A total of 46 A-shares have surpassed the annual line today, with notable stocks including: - Siyuan Electric (002028) with a deviation rate of 7.62% - Huaming Equipment (002270) with a deviation rate of 2.75% - Tongyi Co., Ltd. (300538) with a deviation rate of 2.63% [1] Deviation Rate Rankings - The top stocks with the highest deviation rates from the annual line include: - Siyuan Electric: 10.00% increase, latest price 76.99 yuan, deviation rate 7.62% - Huaming Equipment: 3.25% increase, latest price 16.85 yuan, deviation rate 2.75% - Tongyi Co., Ltd.: 2.63% increase, latest price 16.02 yuan, deviation rate 2.63% [1] Additional Stocks with Minor Deviations - Stocks with smaller deviation rates that have just crossed the annual line include: - Daqin Railway and *ST Haiyuan with minimal deviation rates [1]

Market Overview - The Shanghai Composite Index closed at 3525.40 points, above the annual line, with a change of 0.43% [1] - The total trading volume of A-shares reached 987.43 billion yuan [1] Stocks Breaking Annual Line - A total of 41 A-shares have surpassed the annual line today, with notable stocks including: - Siyuan Electric (002028) with a deviation rate of 7.62% - Tongyi Co., Ltd. (300538) with a deviation rate of 2.51% - Ruisheng Technology (688090) with a deviation rate of 2.05% [1] Stocks with Significant Deviation Rates - The stocks with the highest deviation rates from the annual line include: - Siyuan Electric: 10.00% increase, trading at 76.99 yuan - Tongyi Co., Ltd.: 2.50% increase, trading at 16.00 yuan - Ruisheng Technology: 3.24% increase, trading at 35.10 yuan [1] Additional Stocks with Minor Deviations - Other stocks that have just crossed the annual line with smaller deviation rates include: - Qianjiang Motorcycle, Jiuquan Technology, and Huadian International, which have just reached the annual line [1]

Investment Rating - The report maintains a "Buy" rating for multiple companies in the pharmaceutical sector, including Junshi Bioscience, Hualing Pharmaceutical-B, and others [2]. Core Insights - The report emphasizes the broad market for lipid-lowering treatments, particularly focusing on the competitive landscape of PCSK9-targeted drugs, with approximately 500 million adults in China suffering from dyslipidemia, including 120 million with high cholesterol [3][15]. - The pharmaceutical sector saw a 1.60% increase this week, underperforming the CSI 300 index by 0.35 percentage points, with sub-sectors like medical infrastructure and life sciences performing better than generics and innovative drugs [4][31]. Summary by Sections 1. Industry Perspective and Investment Recommendations - The lipid-lowering market is vast, with intense competition in PCSK9-targeted drugs [15]. - Investment strategies should focus on innovative drugs, particularly in the context of increased liquidity and risk appetite in the market [4][31]. 2. Pharmaceutical Sector Performance - The pharmaceutical sector's performance was mixed, with medical infrastructure and life sciences leading, while generics and innovative drugs lagged [4][37]. - The overall P/E ratio for the pharmaceutical industry is 27.69, with a premium of 35.26% compared to the broader A-share market [37]. 3. Company Dynamics - Notable company announcements include Baiyoutai's licensing agreement for BAT2406 in Latin America and Yifan Pharmaceutical's approval for clinical trials of a growth hormone injection [38][40]. - Companies like WuXi AppTec and Lijun Group have made significant moves, including share buybacks and new product approvals [39][41]. 4. Industry Trends - The report highlights the upcoming patent expirations for major small molecule drugs, which could lead to increased demand for raw materials [5][32]. - The report also notes the expected recovery in overseas demand, which may improve the performance of CXO companies [34]. 5. Research and Development Focus - The report discusses the clinical progress of various PCSK9-targeted therapies, including monoclonal antibodies and gene editing approaches, indicating a strong pipeline in this area [3][23][25]. - The competitive landscape for PCSK9 drugs in China is characterized by pricing and adherence challenges, with several products already on the market [27].